Skip to main content
Smart Investors Daily
GR

NASDAQ · GRNA

GreenLight Biosciences Holdings

Healthcare · Biotechnology

$0.30

Down-$0.00 (-0.03%)

Updated Sep 18, 2026, 1:55 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
45.43M
P/E ratio
-0.24
Dividend yield
0.00%
52-week range
— – —
Volume
143.17K
Avg. volume
713.37K

Price performance

GRNA price history

1M range · 0 trading sessions · Daily adjusted prices

GRNA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest GRNA news

The latest Smart Investors Daily articles mentioning GRNA.

GRNA research

Overview

Company profile and research snapshot.

Company profile

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$11.00
Implied upside
Analysts
GRNA recent ratings
DateFirmRatingTarget
May 31, 2023Canaccord GenuityHold
Dec 8, 2022Canaccord GenuityBuy
Oct 14, 2022Credit SuisseOutperform
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jul 24, 2023

GreenLight Announces Completion of Merger with Fall Line Endurance Fund

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the “NASDAQ”) before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each remaining share of GreenLight common stock not purchased in the Offer (other than shares of GreenLight common stock (i) owned by GreenLight as treasury stock, (ii) owned by Merger Sub immediately before the effective time of the Merger, (iii) that were irrevocably accepted by Merger Sub in the Offer, (iv) held by stockholders who have perfected their statutory rights of appraisal under Section 262 of the DGCL or (v) that are subject to the Contribution and Exchange Agreements entered into between Parent and certain stockholders of GreenLight) will be converted into the right to receive $0.30 in cash, without interest, and subject to deduction for any required withholding taxes.

GlobeNewswire Inc. · May 30, 2023

GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.